Humacyte, Inc

Looking Ahead

Innovative Tissue Engineered Platform
Learn More

Human Acellular Vessel

About Humacyte

Humacyte, a privately held company, is primarily focused on developing investigational products for vascular disease and for replacement of anatomical conduits. The company uses its innovative and proprietary platform technology to engineer human, extracellular matrix-based investigational tissues that can be shaped into tubes, sheets, or particulate conformations, with properties similar to native tissues. Incorporated in 2004, Humacyte has licensed technology from MIT, Yale, and Duke University. Since then, Humacyte has made considerable progress in the development, pre-clinical, and clinical testing of our human acellular vessels (HAV).

Read More »

Investigating the Potential for...

Longer Patency

Pre-clinical and clinical data suggests Humacyte human acellular vessels (HAV) may have the potential to extend patency with the possibility of some reduction in inflammation and some reduction in clotting.

Lower Risk of Immune Response

Humacyte human acellular vessels may have the potential to be less immunogenic with the possibility of some reduction in foreign body response.

Lowering Healthcare Costs

Humacyte human acellular vessels may have the potential to lower healthcare costs with reduced surgical interventions and more positive, long term, clinical outcomes.

Our Affiliates

Duke University
Massachusetts Institute of Technology
AlloSource
Yale University